학술논문

Association of Renin Angiotensin Aldosterone System Inhibitors and Outcomes of Hospitalized Patients With COVID-19
Document Type
article
Author
Gupta, NehaSettle, LisaBrown, Brent RArmaignac, Donna LBaram, MichaelPerkins, Nicholas EKaufman, MargitMelamed, Roman RChristie, Amy BDanesh, Valerie CDenson, Joshua LCheruku, Sreekanth RBoman, KarenBansal, VikasKumar, Vishakha KWalkey, Allan JDomecq, Juan PKashyap, RahulAston, Christopher EMesland, Jean-BaptisteHenin, PierrePetre, HélèneBuelens, IsabelleGerard, Anne-CatherineClevenbergh, PhilippeGranado, Rolando Claure-DelMercado, Jose AVega-Terrazas, EsdenkaIturricha-Caceres, Maria FGarza, RubenChu, EricChan, VictoriaGavidia, Oscar YPachon, FelipeSanchez, Yeimy Aknežević, DanijelKassas, Mohamed ElBadr, MohamedTawheed, AhmedYahia, HendKantas, DimitriosKoulouras, VasileiosPineda, EstelaGuillen, Gabina María ReyesSoto, Helin ArchagaLizardo, Ana Karen VallecilloKopitkó, CsabaBencze, ÁgnesMéhész, IstvánGerendai, ZsófiaDoddaga, PhaneendraChandra, NeethiSegu, Smitha SChakraborty, TuhinJoyce, EpcebhaVadgaonkar, GirishEdiga, RekhaBasety, ShilpaDammareddy, ShwethaKasumalla, Phani SreeharshaRaju, UmamaheswaraManduva, JanakiKolakani, NareshSripathi, ShreejaChaitanya, SheetalCherian, AnushaParameswaran, SreejithParthiban, MageshA., Menu PriyaPrabhu, MadhavJakati, VishalRijhwani, PuneetJain, AshishGupta, AviralJaiswal, Ram MohanTyagi, AmbikaMathur, NimishDaga, Mradul KumarAgarwal, MunishaRohtagi, IshanPapani, SridharKamuram, MaheshAgrawal, Kamlesh KumarBaghel, VijendraPatel, Kirti KumarMohan, Surapaneni KrishnaJyothisree, EkambaramPetrolwala, MukurLadva, BharatDalili, NooshinNafa, MohsenMatsuda, WataruSuzuki, ReinaTahara, ShuSanui, MasamitsuHorikita, ShoItagaki, YukiKodate, Akira
Source
Critical Care Medicine. 50(10)
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Clinical Research
Good Health and Well Being
Adult
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Humans
Hypertension
Male
Middle Aged
Renin-Angiotensin System
Retrospective Studies
COVID-19 Drug Treatment
Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator Group
Nursing
Public Health and Health Services
Emergency & Critical Care Medicine
Clinical sciences
Language
Abstract
ObjectivesTo determine the association of prior use of renin-angiotensin-aldosterone system inhibitors (RAASIs) with mortality and outcomes in hospitalized patients with COVID-19.DesignRetrospective observational study.SettingMulticenter, international COVID-19 registry.SubjectsAdult hospitalized COVID-19 patients on antihypertensive agents (AHAs) prior to admission, admitted from March 31, 2020, to March 10, 2021.InterventionsNone.Measurements and main resultsData were compared between three groups: patients on RAASIs only, other AHAs only, and those on both medications. Multivariable logistic and linear regressions were performed after controlling for prehospitalization characteristics to estimate the effect of RAASIs on mortality and other outcomes during hospitalization. Of 26,652 patients, 7,975 patients were on AHAs prior to hospitalization. Of these, 1,542 patients (19.3%) were on RAASIs only, 3,765 patients (47.2%) were on other AHAs only, and 2,668 (33.5%) patients were on both medications. Compared with those taking other AHAs only, patients on RAASIs only were younger (mean age 63.3 vs 66.9 yr; p < 0.0001), more often male (58.2% vs 52.4%; p = 0.0001) and more often White (55.1% vs 47.2%; p < 0.0001). After adjusting for age, gender, race, location, and comorbidities, patients on combination of RAASIs and other AHAs had higher in-hospital mortality than those on RAASIs only (odds ratio [OR] = 1.28; 95% CI [1.19-1.38]; p < 0.0001) and higher mortality than those on other AHAs only (OR = 1.09; 95% CI [1.03-1.15]; p = 0.0017). Patients on RAASIs only had lower mortality than those on other AHAs only (OR = 0.87; 95% CI [0.81-0.94]; p = 0.0003). Patients on ACEIs only had higher mortality compared with those on ARBs only (OR = 1.37; 95% CI [1.20-1.56]; p < 0.0001).ConclusionsAmong patients hospitalized for COVID-19 who were taking AHAs, prior use of a combination of RAASIs and other AHAs was associated with higher in-hospital mortality than the use of RAASIs alone. When compared with ARBs, ACEIs were associated with significantly higher mortality in hospitalized COVID-19 patients.